Jama Oncology

JAMA Oncology (jama-oncology)

Journal positioning

JAMA Oncology is a JAMA Network specialty journal for clinical and translational oncology research aimed at a broad cancer-care readership — medical, surgical, and radiation oncologists, as well as cancer-epidemiology and outcomes researchers. It favors practice-relevant work: randomized cancer trials, comparative-effectiveness and real-world outcomes analyses, screening and prevention studies, and biomarker work tied to a clinically meaningful endpoint. It is positioned as a general oncology venue with JAMA's emphasis on absolute benefit, toxicity, and patient-centered outcomes, distinct from a society flagship such as Annals of Oncology (ESMO). Single-arm early-phase reports with no comparator, descriptive molecular series, and surrogate-only signals with weak clinical translation are a weak fit. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JAMA Oncology author instructions.

When to trigger

• The author names JAMA Oncology for a clinical, epidemiologic, or outcomes oncology study and wants a fit/framing check.
• A cancer study must be re-framed around a clinically meaningful survival, toxicity, or quality-of-life endpoint for a broad oncology audience.
• The author is choosing between JAMA Oncology, JAMA, and a society or subspecialty oncology journal (e.g., Annals of Oncology).
• The author needs the journal's reporting-guideline, registration, and desk-reject expectations for oncology work.

Scope & topic fit

• Randomized oncology trials (phase 2/3) reporting survival, response, toxicity, or patient-reported outcomes, including practice-de-escalation trials.
• Comparative-effectiveness and real-world-evidence studies using cancer registries, claims, or institutional cohorts with rigorous confounding control.
• Cancer screening, early-detection, and prevention studies with clinically meaningful endpoints and harms accounting.
• Prognostic and predictive biomarker studies validated against an outcome, not just associated with a molecular feature.
• Health-services, disparities, financial-toxicity, and survivorship research in oncology.
• Pooled analyses and meta-analyses answering a focused, decision-relevant cancer question.

Method & evidence bar

• Trials must be adequately powered with a prespecified primary endpoint; overall survival and validated surrogates are preferred, and surrogate-only endpoints need explicit justification of clinical relevance.
• The applicable reporting guideline and checklist are required: CONSORT for trials, STROBE for observational/registry studies, PRISMA for systematic reviews, REMARK-style rigor for tumor-marker work.
• Trials require prospective registration; registration number, protocol, and statistical-analysis plan are expected, including amendments.
• Survival analyses must report absolute differences, hazard ratios with confidence intervals, and adequate follow-up; toxicity (graded per a standard scheme) must be reported alongside efficacy.
• Real-world/registry claims must address immortal-time, selection, and indication bias; causal language must match the design.
• Biomarker claims need a prespecified cut-point, an independent validation set, and reporting of analytic performance.

Structure & house style

• JAMA Network format with a structured abstract and a Key Points box; re-check current article types (Original Investigation, Brief Report, Research Letter, etc.) and limits on the live guide.
• The introduction frames a focused, decision-relevant cancer question; the discussion states the practice implication and net clinical benefit plainly.
• Tables/figures follow JAMA Network statistical-reporting standards; CONSORT/STROBE flow diagrams, Kaplan-Meier curves with numbers at risk, and toxicity tables are expected where applicable.
• Supplements carry the protocol, SAP, full toxicity and subgroup analyses, and consort/biomarker checklists.